Orofacial pain: Diagnosis and management

Tara Renton

Webinar: June 2011
An update

What is pain?
- Types of pain
- How do we feel it?

Orofacial pain
- Diagnosis
- Management

Cases
The Greek goddess of revenge ‘Poine’

- was sent to punish the mortal fools who had angered the gods.

- Poine also gave us our word "pain"

- Many ancient cultures believed pain and disease were punishment for human folly. "Magic and ritual were very common in ancient cultures"
‘Anaesthesia’

coined by Oliver Wendel Holmes, Sr. (1809–1894) in 1846 from the Greek αν-, an-, "without"; and αἰσθησις, aisthēsis, "sensation") refers to the inhibition of sensation

Analgesia

is the absence of pain

Pain

“An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage” (IASP, 1979).
Understanding pain

- Galen (129-216), who described a network of nerves leading to the brain

- Mainonides (1138-1204): Galens art heals only the body but Abou Amrans heals the body and soul’

- Descartes (1596-1650) who first stated that pain was experienced in the brain, rather than in the heart as was the accepted Aristotelian doctrine
Gate Theory of pain

Canadian psychologist Ronald Melzak and British physiologist Patrick Wall (1965)
Celsus (25 BC) remarks that toothache “can be counted among the greatest of torments”

"For there was never yet philosopher that could endure the toothache patiently."

What is pain?

- Subjective sensation: with physical and psychological effects
- Individual response: dependant on age / gender / experience / personality / anxiety; settings / trust in clinician / fatigue
- Organic and or psychological cause
- Measure: questionnaires to assess disability; physical / mental

www.kcl.ac.uk
HOW DO WE FEEL THE "OUCH"?
Pain Process

1. Nociception
2. Sensation
3. Behaviour
4. Suffering

Bio psycho social Model

- Social / cultural
  - Age, gender, race, peer support, familial expectation

- Cognitive / conceptual
  - Memories past experience, secondary gain, threat perception

- Emotional / psychological
  - Depression, anxiety, stress, fear, anger
NEURAL PROPAGATION OF PAIN
Nociception

- Tissue damage
- Chemical and electrical events
- Activation of the sensory cortex
- Pain recognition
Noxious stimulus
What events unfold in the sensory system?

**Neurophysiological**
- Peripheral nervous system PNS
  - Inflammation
  - Receptors
  - Axons (primary / secondary / tertiary [cortex])
  - Neurotransmission
- Central nervous system CNS
  - Pain pathways

**Patient**
- Clinical symptoms
- Psychological factors
- Environmental factors
- **Reaction is Emotional and Physical**
Specific pain receptors

- Transmitters
  - ↓NGF, ↓SP, ↓CGRP

- Receptors
  - ↓TRPV1, ↓P2X3

- Ion Channels
  - Na, Ca, K

- Anatomy
  - degeneration

- ↑spontaneous activity
Peripheral Acute inflammatory pain

**Tissue injury**

**Cell damage**
- Trauma mechanical, chemical, Radiation, heat

**Cytokine release**
- Attract immune cells
- Nerve activation via receptors via NGF

**Neural depolarisation (PNS)**
- Action potential
- Signals primary, secondary, tertiary (CNS)
- Cortical activation ‘sensing’
- Reaction (motor and sensory)

**More cytokine release NEUROINFLAMMATION**

**If process prolonged = changes in nervous system**

**Chronic non inflammatory pain**

**Keratinocyte**
- Phospholipase A
- Prostoglandins
- Leukotrienes

**Platelet serotonin**

**H+ K+**
- Mast cells histamine

**Bradykinin**
- Nerve growth factor NGF
CNS and PNS

**Receptor**

**Primary sensory nerve**
- A Delta and C fibres

**Secondary sensory nerve**
- Lamina I DRG

**Tertiary sensory nerve**
- Specific areas of the brain
  - Thalamus
  - Anterior cingulate cortex
  - S1 / S2
  - Insula
  - Brainstem
SENSATION
Central neuroanatomy

- Pain related areas
  - Spinal cord C1–S5
    - C1–8/T1–12/L1–5/S1–5
    - distal root ganglion
  - Ventral horn = motor
  - Dorsal horn = sensory

- Specific areas of the brain
  - **Brainstem**
    - Cranial nerve
    - Thalamus
    - Hypothalamus
    - Cerebellum
  - **Forebrain**
    - Cortex—sensation
      - Anterior cingulate cortex
    - S1 and S2
    - Limbic system—memory
    - Basal ganglia—movement
Anatomy revisited

- Additional amygdala, hippocampus, brainstem, and V5 ROIs

ACC

S1

S2

THAL

PCC

INS
Main effect of TME pain, right tooth, cluster corrected $\alpha < 0.05$
Central pain activity

- Pain related areas
  - Spinal cord C1-S5
    - C1-8/T1-12/L1-5/S1-5
  - Distal root ganglion
    - Ventral horn = motor
    - Dorsal horn = sensory
- Brain stem
  - Cranial nerve
  - Thalamus
  - Hypothalamus
  - Cerebellum
- Forebrain
  - Cortex - sensation
  - Limbic system - memory
  - Basal ganglia - movement
Behaviour

- History
- Stress
- Anxiety
- Culture
- Ethnicity
- Beliefs
- Age
- Environment
- Context
Affective emotional areas of Brain

- Neuromatrix model
  - Somatosensory cortex
  - Thalamus
  - Spinothalamic nerve tract
  - Sensory neurons
  - Spinal cord
- Homeostatic model
  - Anterior cingulate
  - Parieto-insular cortex
  - Multiple spinothalamic fibre types
  - Sensory neurons
  - Spinal cord

www.kcl.ac.uk
Perception of pain
Perception of pain

‘I enjoy the pain’
David Beckham on tattoos

Opus Dei Priest ‘Pain is good’
Suffering

History
Stress
Anxiety
Culture
Ethnicity
Beliefs
Age
Environment
Context

Personality
Religion
Placebo
Anger
Catastrophising
Fear
Genetics and pain

- Tmp21-I (p23) (AJ004912)
- Cil methylsterol oxidase (C200556)
- Protein convertase subtilisin/kexin type 5 (U4701)
- Adaptor-related protein complex 2 alpha (K53773)
- Calmodulin-dependent calcineurin A alpha (M29275)
- Neurabin I (AF010252)
- GRQ protein (L14462)
- Complex I (D20817)
- Chromogranin A (X06832)
- Preopio regulatory factor-2 (X53232)
- Type II brain d. 1 (A2033937)
- Palmitoyl-protein thioesterase 1 (L34262)
- Chromolink receptor-like 1 (AJ092748)
- ICAM-1 (NM_013967)
- Gamma-glutamyl hydrolase (U355179)
- S2K (LD1524)
- Cathepsin heavy chain (J03583)
- Fructose calyx protein 1 (AF101046)
- Lost on transformation (U72620)
- Synaptopodin 1 (U43519)
- Testis-specific AKAP (A002476)
- BPH protein (J000011)
- Calcium-binding protein 1 (Y17048)
- Synaptotagmin 3 (D20512)
- Cytochrome c oxidase Va (Y37257)
- Tyrosine phosphatase-like (D39222)
- Slack (A206977)
- Apolipoprotein E (J02582)
- Isocitrate dehydrogenase (X74126)
- WAP four-disulfide core domain (AF037272)
- Nociceptin and CRF substrate in neurons 1 (AF104402)
- Hap515 (AF187860)
- Urythropyridine reductase (J03481)
- VGF, NIFG inducible (M00525)
- CGRP (L0031)
- Hap27 (M86386)
- RT1.Va (D2671)
- Porcupine (AF201679)
- RT1.Ib (D45762)
- C1q beta (X71127)
- TIMP-1 (L31883)
The Human Genome

- 3.16 billion base pairs
- 23 pairs of chromosomes
- Human Genome Project has sequenced about 2.8 billion base-pairs to date
- Only 3% of the human genome actually code for proteins
- About 15% of the non-coding DNA in humans is conserved (functional importance)
The genetic basis of V pain

"Human genetics has showed us how the risk of pain is reduced naturally.

GCH1 was the first human gene variant ever associated with the intractable hurt caused by nerve damage.

Nature on 14 December 2006
Six children from three related Pakistani families feel no physical pain.

Although capable of feeling other sensations like warm and cold they have a lack of pain perception have.

- All six have had lip injuries
- Two lost one-third of their tongues
- Most suffered fractures or bone infections
- Some have been scalded by boiling liquids or steam
- Others burned from sitting on radiators

**SCN9A** gene polymorphism resulting in Nav 1.7 sodium channel deficiency.
The COMT protein is a brain janitor and metabolizes the brain chemicals called dopamine and norepinephrine.

Dopamine is often known as the brain's "pleasure chemical", because of its role in transmitting signals related to pleasurable experiences.

If you have:
- two copies of the **val** form of COMT that mops up dopamine rapidly
- two copies of the **met** form of the gene make only poor COMT, and can't "clean up"
- one copy of each gene variety -- the majority of people -- make some of each kind of COMT, yielding a "normal" dopamine-metabolizing system.

The differences between met/met and val/val participants in the activation of the mu-opioid system were most significant in the cingulate cortex, thalamus and the **nucleus accumbens**
Genetics of pain

- Red heads have more pain
- Melanocortin 1 receptor
  def
- 20% increase pain
- Melanocortin–1 Gene for Red Hair and Pain Tolerance
- “It does appear that redheads have a significantly different pain threshold and require less anaesthetic to block out certain pains,”
- Muopoid receptor
Candidate genes so far

- **COMT** (Seeman et al., 2005; Diatченко et al., 2004)
- **DRD4** (Benjamin et al., 1996, Ebstein et al., 1996)
- **GCH1** (Tegeder et al., 2006)
- **CYP2D6** (DeLeon et al., 2003; Ammon-Treiber et al., 2003)
- **DAT1** (Mill et al., 2006)
- **OPRM** (Fillingim et al., 2005, Kim et al. 2004)
- **TRPV1** (Kim et al. 2006)
- **IL1** (Solovieva et al., 2004)
- **IL6** (Noponen-Hielta et al., 2005)
- **SCN9A** (Cox et al., 2006)
The future of pain genetics

- Improved diagnostics and patient care
  • (e.g. „customised“ medication) with side effect reduction, risk management

- Cost of genetic analyses will decrease

- More information on biological functions of genes and proteins
  • (imaging genomics, proteomics, QST)

- Increased interdisciplinary work
  • Epigenetics will receive increased attention

- Increasing numbers of papers on pain genetics
TYPES OF PAIN
Pain: Acute

‘Healthy pain’ due to inflammation

Infection / autoimmune / trauma

Thermal / mechanical / chemica
Chronic Pain

Unhealthy / Neuropathic pain lasting > 3 months

Back pain 47.5%
Head ache 45.2%
Joints 41.7%

Disease of the neuromatrix
Chronic pain: consequences UK

- 33% of UK population suffer
- 13% work force is compromised
- Diabetic and HIV neuropathy
- Accounts for £40 million GNP / year UK
Consequences of pain: US

Side effects are a major hurdle in treating chronic pain, which costs the United States around $100 billion annually in treatment and lost wages.

About 50 million adults in the United States suffer from chronic or persistent pain, according to an article on the subject in the journal Science.

Accounts for more than 20 percent of doctor's visits and 10 percent of the trillions of dollars spent on health care.
Why does pain become chronic?

- **Persistent acute stimulus becoming chronic**
  - Increased sensitivity of CNS to peripheral stimulus

- **Neuroplasticity**
  - Interaction between PNS and CNS results permanent changes in system

- **Memory of pain**
  - Somatosensory cortex changes

- **Genetic predisposition**
Trigeminal nerve pain

Education

Complex region

Consequences

- Social function
- Eating
- Drinking
- Speaking
- Kissing
- Make up / shaving
- Sleeping
Trigeminal nerve

Sensory supply to face, scalp and mouth

Homunculus
Causes of peripheral sensory nerve neuropathy

<table>
<thead>
<tr>
<th>Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
</tr>
<tr>
<td>PHN</td>
</tr>
<tr>
<td>Chemotherapy</td>
</tr>
<tr>
<td>MS</td>
</tr>
<tr>
<td><strong>Post surgical traumatic neuropathy</strong></td>
</tr>
<tr>
<td>Parkinson’s</td>
</tr>
<tr>
<td>Malignancy</td>
</tr>
<tr>
<td>Drugs – Growth hormone injections</td>
</tr>
<tr>
<td>Kehlet et al, 2006 in Lancet</td>
</tr>
<tr>
<td>------------------------------</td>
</tr>
<tr>
<td>Amputation²</td>
</tr>
<tr>
<td>Breast surgery (lumpectomy and mastectomy)³</td>
</tr>
<tr>
<td>Thoracotomy⁴⁻⁷</td>
</tr>
<tr>
<td>Inguinal hernia repair⁸⁻¹⁰</td>
</tr>
<tr>
<td>Coronary artery bypass surgery¹¹⁻¹³</td>
</tr>
<tr>
<td>Caesarean section¹⁴</td>
</tr>
</tbody>
</table>

*Gall bladder surgery not included, since preoperative diagnosis of pain specifically from gall bladder is difficult and persistent postoperative pain could therefore be related to other intra-abdominal disorders. †National Center For Health Statistics, Ambulatory and Inpatients Procedures, USA, 1996.

**Table 1: Estimated incidence of chronic postoperative pain and disability after selected surgical procedures**

30% get persistent pain 10% are severely affected

? 4–5% of trigeminal severely affected
Post traumatic neuropathy of the trigeminal nerve

Local anaesthesia
Third molar surgery
Implants
Endodontics
Orthodontics
Orthognathic surgery
Fractures
Pathology

Tara Renton Premier symposium 2010
THE CONSEQUENCES OF TRIGEMINAL NERVE INJURY
Impact of orofacial pain

70% psychological impact
Locker & Grushka 1987

48% psychosocial impact
Richards & Slade 1996

In TMJ pain:
29% high disability resulting in unemployment
Von Korff et al 1992

64% decreased efficiency at work
Dao et al 1994
Interference of symptoms with the lifestyle for IANI and LNI patients.
## Classification of Chronic Orofacial Pain

<table>
<thead>
<tr>
<th>Neurovascular</th>
<th>Neuropathic</th>
<th>Idiopathic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tension HA</td>
<td>Trigeminal N</td>
<td>Burning Mouth S</td>
</tr>
<tr>
<td>Migraine</td>
<td>Typical / atypical PHN</td>
<td>TMJ pain</td>
</tr>
<tr>
<td>Cluster HA</td>
<td>PHN</td>
<td>Persistent idiopathic (ATFP / ATO)</td>
</tr>
<tr>
<td>Giant cell arteritis</td>
<td>Glosspharyngeal N</td>
<td></td>
</tr>
<tr>
<td>SUNCT</td>
<td>Post surgical N</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lingual inferior alveolar nerve injuries</td>
<td></td>
</tr>
</tbody>
</table>
Neurovascular

- Exclude sinister headaches 1%
  - >50 yrs Tumour 1%
  - Subarachnoid haemorrhage – recent trauma LoC

- Migraine 10-17%
  - Five or more lifetime headache attacks lasting 4-72 hours each and symptom-free between attacks
  - moderate to severe pain, unilateral +/- aura visual signs

- Cluster headaches 5% - SUNCT
  - Male:female ratio 4:1 to 20:1 / 30yrs +
  - Severe episodic pain lasting 15-180 minutes
  - Unilateral Orbital, supraorbital or temporal
  - 8x a day to every other day for a period of 2 -12 weeks

- Tensions type headaches
  - 30-78% population -Highest socioeconomic impact
  - At least 10 episodes occurring <1 day a month on average
  - Infrequent episodes lasting from 30 minutes to 7 days
  - Typically bilateral

- Medication over use headaches 30-78%
What is the impact on daily life?

Exclude sinister headache <1%

Low
Episodic tension headache ETTH 40-60%

High
How many headaches per month?

>15
Cluster headache 5%

<15
Migraine 10-12%

How many days a week?

<2 non medicate

> 2 medicate

With or without Aura
Neuropathic OFP with ‘neuralgia’

- **Trigeminal neuralgia (TN)**
  - Typical
  - Atypical
- **Post herpetic neuralgia (PHN)**
  - > 50 yrs 60% likely to develop pain post shingles
  - Ramsay Hunt syndrome
- **Glossopharyngeal neuralgia**
  - Acute pain pharynx, tongue base, mastoid regions
- **Post traumatic V neuralgia**
  - Lingual nerve injuries
  - Inferior alveolar nerve

**BMS?**

V neuralgia seen in patients with:
- Diabetes
- HIV
- Chemotherapy
- MS
Idiopathic chronic OFP

TMJ pain
- Functional – chewing gum
- Myofacial
- Arthritides
- Derangement

BMS
- ? neuropathy

Persistent idiopathic
- Extraoral / facial
- Intraoral / odontalgia
TRPV1 -IR

Control

BMS

TRPV1 fibres staining in control and in BMS x20.

Bar chart shows the mean ± SEM of % area of TRPV1 fibres in control (n=10) and BM (n=10) tongue. * P = 0.0011
ASSESSMENT OF PAIN
Pain’s multiple components

- nociception / sensation / suffering / behavior

Disability

- lack of mobility, inability to work, difficulty in interpersonal relationships

Multiple components of pain assessment

- physical location of pain, description tools
- functional tools: sickness/impact profile, pain disability index
- behavioral/cognitive drug use, physician visits
- economic
- Socio-cultural, litigation, patient independence, quality of life, family dynamics, patient goals.
Exclude systemic and local pathology

**Bloods**
- FBC, haematinic (folate, B12, ferritin)
- Thyroid function tests
- HBA1c
- Zinc levels
- ENAs and ANAs
- Us+Es required for contrast
- Gadolinium MRI scan
Exlude central pathology

Classical TN
- vascular compression

Multiple sclerosis
- MRI plaques

Stroke

Vasculitis

Post herpetic neuralgia

Tumours
- Meningioma
Pain assessment

- Diagnosis of pain
- Pain History
- Pain thresholds
- Subjective measurement of pain
- Indirect measurement of pain
- Objective assessment of pain
Phenotyping of patients

- Imaging
- Genetic
- Pain
- Neurological
- Functional
- Psychometric
  - Patient demographics
Assessment - Measurement Tools

- Pain history
- Examination
  - Psychometric
    - Subjective pain scores
      - VAS, pain descriptors
    - Affective
      - Anxiety depression FUNCTIONALITY - disability
  - Psychophysical
    - Neurophysical tests - neuropathic area
      - Cold warm / Mechanosensory / Vibration
      - Special sensory = Taste
Pain history

- **Site**
- **Duration**
- **Frequency**
  - Constant (burning throbbing)
  - Spontaneous / evoked (cause / relief)
- **Character**
  - **Type**
    - burning, stabbing
  - **Intensity**
- **Persistent / intermittent**
- **Localisation**
- **Radiation**
- **Associated signs - redness swelling**

**Pain Descriptors**

**Steady Pain (97%)**
- Burning
- Aching
- Stinging
- Throbbing
- Itching
- Numbing
- Pins & Needles
- Pulling

**Brief Pain (87%)**
- Sharp
- Jabbing
- Shooting
- Electric

**Evoked Pain (87%)**
- Mechanical
- Thermal

Psychometrics

- Measure
  - Affective
    - Anxiety
    - Depression
  - Beliefs
  - Fear
  - Anger
  - Coping
Visual Analogue Scales

Anchors:

no pain  max pain

eideneurolearningblog.blogspot.com/2005_02_25...
:www.mindhacks.com/blog/linkage/index.html

10 cm line
Assessment - neuropathy

- VAS
  - At rest
  - Dynamic allodynia
  - Cold allodynia
  - capsaicin
- Mechanosensory
  - Von Frey
  - Neuropathic area
- Local analgesia
- Thermo sensory
- Biopsy
What are the problems?
With current assessment of trigeminal function

- Solely mechanosensory (large fibres only)
- Taste tests unreliable
- Pain and altered sensation often overlooked
Psycho physical testing
Quantitative thermo sensory testing
Assessment fMRI functional magnetic resonance imaging
Anatomy revisited

• Additional amygdala, hippocampus, brainstem, and V5 ROIs
MANAGEMENT OF PATIENTS AND PAIN
Manage the Pain Process

Bio psycho social Model

Nociception

Social / cultural
Age, gender, race, peer support, familial expectation

Sensation

Cognitive / conceptual
Memories past experience, secondary gain, threat perception

Behaviour

Emotional / psychological
Depression, anxiety, stress, fear, anger

Suffering
Manage the Pain Process

Bio psycho social Model

Social / cultural
Age, gender, race, peer support, familial expectation

Emotional / psychological
Depression, anxiety, stress, fear, anger

Cognitive / conceptual
Memories past experience, secondary gain, threat perception

LA, Spinal Block
Membrane stabilising drug

Sedation, CBT
CBT
Management

Inflammatory or neuropathic pain?

Patient factors

Environment

Investigations
  • Psychological
  • Medical
  • Surgery
  • Combination
Opium is a Middle English word (c1100–c1500 AD) of Greek origin that passed through Latin into English.

Opium is a diminutive of the ancient Greek opos “milky juice of plant”

A Brief History of Pain Relief:
http://www.tylenolliverdamages.com/timeline.html
Management tools

Counselling
- Reassurance and explanation

Medical symptomatic therapy (pain or discomfort)
- Topical agents for pain
- Systemic agents for pain

Surgical intervention
- LA diagnostic / therapeutic block Greater occipital nerve block
- Cryo/glycol/thermocoag/gamma knife
- MVD microvascular decompression
Management of affective /behavioural problems

- All patients were ‘counselled’
- Liaison psychiatry
- Development of a tailored Cognitive behavioural therapy programme
- Patient website NEW
- Patient days NEW
- 50% Chronic pain sufferers are depressed Wesseley S 2010
- CBT was offered to 8% of patients
Management of affective or behavioural problems

Liaison psychiatry

Cognitive behavioural therapy

Findings:

PTSD

Victim of abuse

50% Chronic pain sufferers are depressed Wesseley S 2010

Tara Renton Premier symposium 2010
MEDICATION FOR ACUTE PAIN
Inflammatory (acute) pain

Responds to OTC analgesics

Chronic pain

does NOT respond to OTC drugs
Guidelines (J One Day Surg 1997)

❖ Mild
   ❖ Cystoscopy/peripheral surgery/grommets
     ❖ Tylex (codeine 30mg/paracetamol 500mg QDS)

❖ Moderate
   ❖ Varicose veins/adult circumcision/TOP/D+C
     ❖ Tylex +Diclofenac (50mg QDS)

❖ Severe
   ❖ Laparoscopy/hernia repair/vasectomy/testicular surgery/dental procedures
     ❖ Tramadol QDS
Where do drugs work?

- NSAIDS peripheral block – cyclooxygenase
- Paracetamol: ? central block – cyclooxygenase
- Opiates central block of NMDA receptors
- Local analgesia blocks all sodium nerve channels (motor and sensory)
- Sedation blocks central GABA receptor pathway = anxiolytic
Seymour 1985
indications in dentistry mainly post op or supplemental for infections

Oral paracetamol +/- NSAIDS

Oral NSAIDS +/- paracetamol

Opioid - injection / epidural / PCA
SYDNEY STICK MAN
IASP approved model for pain therapy

1. Decrease noxious stimuli
   Correct – diagnosis
   Steroids / NSAIDS

2. Raise threshold
   Care concern counselling
   Anxiolytic/antidepressant

3. Consider opioids
   Codeine
   Morphine/methadone

4. Diagnose neuropathic pain
   Anticonvulsants+ /−
   Corticosteroid
DPF

- Aspirin dispersable 300mg (1g)
- Ibuprofen tabs 200mg
  - Propionic acid derivative
- Ibuprofen oral suspension 100mg/5ml
- Diflunisal tabs 250mg
  - Difluorophenyl derivative (Inc dry socket)
- Paracetamol tab 500mg
  - Acetaminophen – analine derivative
- Paracetamol sol tab 500mg
- Paracetamol oral susp 250mg/5ml
- Dydrocodeine tabs 30mg
- Pethidine tabs 50mg
  - Synthetic opioid
Efficacy of analgesics expressed as need to treat (ntt)

- Diclofenac 2.3
- Ibuprofen 400 2.6
- Morphine 3.3
- Ibuprofen 200 4.4
- Paracetamol + dextropropoxyphene 3.3
- Paracetamol 4.8
- Tramadol 5.2
- Aspirin codeine 5.6
- Dextropropoxyphene 7.7
- Tramadol 8.3
- Dihydrocodeine 9.7
- Codeine 10.7
Medications for Chronic pain

- Neuralgic pain
  - Oxcarbazepine
  - Neurontin pregabalin
  - Gabapentin
- Burning chronic pain
  - Nortriptyline > Amitriptyline
- 5% pts persisted with systemic meds
- 18% IANI used topical medication
Chronic OFP

- LA block
  - If pain does not go then pain must be centrally mediated (not peripheral)
- Conventional analgesics do not work
Lidocaine

- Na Channel blocker
- Diagnostic blocks
- Topical patches
  - Versatis 5% Lidocaine
- IV for severe breakthrough
Conventional surgical management

CUT SLASH FREEZE or BURN!
Conventional surgical management

CUT SLASH FREEZE or BURN!
Chronic pain management

Peripherally altered ion channel expression and activity:
- Lidocaine
- Lacosamide
- Carbamazepine
- Gabapentin
- Pregabalin

Spinally increased calcium channel activity:
- TCA / SNRI (Duloxetine, Venlafaxin)

Central decreased descending facilitation inhibition:
- 5HT (Clonidine, NMDA antagonist)
- TCA / SNRI (Duloxetine, Venlafaxin)
- TCA / SNRI (Duloxetine, Venlafaxin)

Wind up inhibition:
- 5HT

www.kcl.ac.uk
As of June 2005 only five drugs had been approved by the Food and Drug Administration to treat neuropathic pain:

- gabapentin, marketed by Pfizer as Neurontin, the gold-standard drug used in over 50 percent of cases and originally developed to treat depression;
- lidocaine, marketed by Endo Pharmaceuticals as Lidoderm, a local anesthetic;
- carbamazepine, originally marketed by Novartis as Tegretol, an anti-convulsant;
- duloxetine, an anti-depressant marketed as Cymbalta by Eli Lilly, and
- pregabalin, also marketed by Pfizer as Lyrica, another anti-depressant.

Neurontin recently lost its patent protection in the United States, and a number of generic versions are now available.

Most of these drugs need to be taken four times a day, opening a space for a pharmaceutical that requires less from the patient.
Chronic pain medication

- Local Analgesics
  - Topical / systemic

- Antidepressants
  - Selective Serotonin Reuptake Inhibitors (SSRI)
  - Selective Norepinephrine Reuptake Inhibitors (SNRI)
  - Monoamine Oxidase Inhibitors (MAOI)
  - Noradrenergic and Specific Serotonin Antidepressants (NaSSA)

- Antiepileptics
  - Tegretol – carbamazepine
  - Oxcarbazepine
  - Lacosamide
  - Alpha 2 delta ligands - Pregabalin / Gabapentin

- NMDA antagonists
  - Opioids / opiates / ketamine

- Others
  - Capsaicin
  - Alpha lipoic acid 600mg/day
Antidepressants

- TCAs
- Selective Serotonin Reuptake Inhibitors (SSRI)
- Selective Norepinephrine Reuptake Inhibitors (SNRI)
- Monoamine Oxidase Inhibitors (MAOI)
- Noradrenergic and Specific Serotonin Antidepressants (NaSSA)
Tricyclic Antidepressants

- Tricyclic antidepressants were introduced in the late 1950s and early 1960s.
- They block the reuptake of norepinephrine by the presynaptic cell, thereby increasing its concentration in the synaptic cleft.
- Tricyclic antidepressants include:
  - nortryptiline (Pamelor™)
  - maprotiline (Ludiomil™)
  - desipramine (Norpramine™)
  - amitryptiline (Elavil™)
  - clomipramine (Anafranil™)
  - imipramine (Trofranil™)
- Side effects
  - affect heart rate and blood pressure
  - postural hypotension
  - Tachycardia (rapid heart rate)
  - dry mouth, urinary retention and blurry vision
  - Physicians must monitor the patient closely for toxic side effects.
  - Tricyclic antidepressants are nonselective inhibitors of norepinephrine reuptake because their chemical structures look like norepinephrine.
Selective Serotonin Reuptake Inhibitors (SSRI)

- introduced in the mid-1980s. SSRIs block the transport of serotonin back into the presynaptic cell, increasing stimulation of the postsynaptic cells.

- SSRIs include the following drugs:
  - fluoxetine (Prozac™)
  - paroxetine (Paxil™)
  - sertraline (Zoloft™)
  - fluvoxamine (Luvox™)
  - citalopram (Celexa™)
  - escitalopram (Lexapro™)

- some patients may experience more side effects with one type of SSRI than with another. Most of the time, patients have to take antidepressants more than once per day.

- fluoxetine has a longer half-life -- it remains in the body longer, so patients can usually take it once a day. This lowers the chance of missing a dose. At high doses, paroxetine and sertraline will interfere with dopamine and serotonin neurotransmission.
SNRIs

- Serotonin–Norepinephrine Reuptake Inhibitors (SNRI) introduced in the mid-1990s
- block the reuptake of both serotonin and norepinephrine by binding to the transporters of these neurotransmitters on the presynaptic cell.
- SNRIs include:
  - bupropion (WellbutrinTM) -- blocks dopamine and norepinephrine reuptake as well
  - duloxetine (CymbaltaTM)
  - venlafaxine (EffexorTM)
- side effects of these drugs are similar to, but less than, those of SSRIs. Bupropion and duloxetine, in particular, have minimal side effects in the areas of sexual dysfunction and weight gain.
Monoamine Oxidase Inhibitors (MAOI)

- An enzyme called monoamine oxidase can degrade serotonin and norepinephrine in the synaptic cleft and presynaptic cell. MAOIs block this degradation, increasing the concentration of the neurotransmitters.

- MAOIs include:
  - phenelzine (Nardil™)
  - tranylcypromine (Parnate™)
  - selegiline (Eldepryl™)
  - isocarboxazid (Marplan™)
  - moclobemide (Manerix™)

- can interfere with norepinephrine - cardiovascular side effects.

- patients must limit their consumption of foods containing tyramine because the drugs interact with tyramine to cause hypertension.

- Tyramine can be found in foods like soy sauce, sauerkraut, chicken and beef livers, aged cheese, sausage, cured meat and fish, yogurt, raisins, figs and sour cream. Patients also have to refrain from consuming alcohol when on these antidepressants. Because of these interactions, doctors do not prescribe this class of antidepressants as frequently as others.
Migraine
**Antiepileptics**

- Tegretol - carbemazepine
- Oxcarbazepine
- Pregabalin
- Gabapentin
- Topiramate
- Lacosamide
- Clonazepam is a benzodiazepine
- NMDA antagonists?
  - Opioids / opiates / ketamine / methadone
- Others
  - Capsaicin
Problems with medication for pain

- Still only 40% of patients get 50% pain relief with best drugs
- Side effects for example Pregabalin
  - Dizziness, somnolence, sexual difficulties, confusion
  - Weight gain TCA GP PGB Dulox
- Elderly people more sensitive to postural hypotension
- CV disease avoid TCAs and carbamazepine
- Epilepsy avoid TCAs
- Bipolar disorder avoid TCA
- Renal impairment avoid gabapentin
Specific management of orofacial pain

- Evidence based where possible
# Classification of Chronic Orofacial Pain

<table>
<thead>
<tr>
<th>Neurovascular</th>
<th>Neuropathic</th>
<th>Idiopathic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tension HA</td>
<td>Trigeminal N</td>
<td>Burning Mouth S</td>
</tr>
<tr>
<td>Migraine</td>
<td>Typical / atypical</td>
<td>TMJ pain</td>
</tr>
<tr>
<td>Cluster HA</td>
<td>PHN</td>
<td>Persistent idiopathic</td>
</tr>
<tr>
<td>Giant cell arteritis</td>
<td>Glosspharyngeal N</td>
<td>(ATFP / ATO)</td>
</tr>
<tr>
<td>SUNCT</td>
<td>Post surgical N</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lingual inferior alveolar nerve injuries</td>
<td></td>
</tr>
</tbody>
</table>
Management of chronic orofacial pain

- Neurovascular & Tension type
  - Tension type headache
  - Migraine
  - Cluster headache
  - Giant cell arteritis
- Neuralgia
  - Trigeminal neuralgia
  - Post herpetic neuralgia
  - Post traumatic sensory nerve injury
- Persistent idiopathic
  - TMJ arthromyalgia
  - BMS

- Counselling
  - CBT
- Drugs
  - Opiate/opioids
  - TCAs Antidepressants
  - Tricyclic antidepressants
  - SNRIs
  - Anticonvulsants
- Topical local analgesia
- Other compounds
  - Capsaicin
Management of headaches

The vast majority of episodic, impactful headaches reported by patients are caused by migraine.

- **Intermittent mild-to-moderate migraine**
  (+/− aura)
- **Intermittent moderate-to-severe migraine**
  (+/− aura)
- **Aspirin/NSAID (large dose)**
- **Aspirin/paracetamol plus anti-emetic**
- **Oral triptan**
- **Nasal spray/subcutaneous triptan**
Chronic OFP
Neurovascular & Tension type Headache

Acute headache
- Migraine
- ETTH
- Other
  (Episodic tension type headache)

Chronic headache
- < 1 hour
- > 4 hour
- Cluster
  - daily
  - Other
- Chronic

IHS Classification of Headaches
- Tension Type Headaches
- Migraine
- Cluster Headache
Exclude sinister headaches

- Subarachnoid haemorrhage - recent trauma LoC
- Cranial arteritis
- Tumour 1%
- >50 yrs
- New-onset, acute headaches associated with other symptoms
  - e.g. rash, neurological deficit, vomiting, pain/tenderness, accident/head injury, hypertension
  - Neurological change/deficit does not disappear when the patient is pain-free between attacks
- Develop algorithm for sinister headaches
## Classification of Chronic orofacial pain

<table>
<thead>
<tr>
<th>Neurovascular</th>
<th>Neuropathic</th>
<th>Idiopathic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tension HA</td>
<td>Trigeminal N</td>
<td>Burning Mouth S</td>
</tr>
<tr>
<td>Migraine</td>
<td>Typical / atypical PHN</td>
<td>TMJ pain</td>
</tr>
<tr>
<td>Cluster HA</td>
<td>Glosspharyngeal N</td>
<td>Persistent idiopathic (ATFP / ATO)</td>
</tr>
<tr>
<td>Giant cell arteritis</td>
<td>Post surgical N</td>
<td></td>
</tr>
<tr>
<td>SUNCT</td>
<td>Lingual inferior alveolar nerve injuries</td>
<td></td>
</tr>
</tbody>
</table>
Post ophthalmic herpes zoster – hyperaemia and corneal scarring
Post Herpetic Neuralgia

- 20% of patients (60%>50yrs) progress to neuropathic pain after Shingles caused by a reactivation of the varicella-zoster virus (VZV).
- In the trigeminal system most commonly V1 and V2
- If patient is <40 years check immuno status (15 times higher in HIV-infected patients)
  - If caught early treat with high dose ant-IFungals
    - Acyclovir (Zovirax)†800 mg orally five times daily for 7 to 10 day 10 mg per kg IV every 8 hours for 7 to 10 days
    - Prednisone 30 mg orally twice daily on days 1 through 7; then 15 mg twice daily on days 8 through 14; then 7.5 mg twice daily on days 15 through 21
- Ramsay hunt syndrome HZ of geniculate ganglion (facial nerve, CT)
Management of Post herpetic neuralgia

- High dose steroids and antivirals (Acyclovir) during acute infection phase
  - If caught early treat with high dose antifungals
    - Acyclovir (Zovirax)†800 mg orally five times daily for 7 to 10 day 10 mg per kg IV every 8 hours for 7 to 10 days
    - Prednisone 30 mg orally twice daily on days 1 through 7; then 15 mg twice daily on days 8 through 14; then 7.5 mg twice daily on days 15 through 21
    - Amitriptyilne
Management traumatic nerve injury

- Counselling
- CBT

- Medical
  - Antidepressants
    - Tricyclic antidepressants
      - Amitriptyline
      - Nortriptiyine
  - Anticonvulsants
    - Carbamazepine
    - Gabapentin
    - Pregabalin

- Surgery early repair / late exploration repair
  - 90% patients feel as though surgery is worthwhile (Robinson PP et al., 2003)
Trigeminal Neuralgia

IASP defines trigeminal neuralgia as “a sudden, usually unilateral, severe, brief, stabbing, recurrent pain in the distribution of one or more branches of the fifth cranial nerve.”
Trigeminal Neuralgia

- **Character**
  - Flashing, shooting, sharp, unbearable
- **Severity**
  - Moderate to severe
- **Site, radiation**
  - Distribution of trigeminal nerve
- **Duration, periodicity**
  - Bouts last for seconds, pain free periods

- **Provoking factors**
  - Light touch, eating, talking
- **Relieving factors**
  - Avoid touch, anticonvulsants
- **Associated factors**
  - Trigger areas, weight loss
TN Investigations

- MRI – patients under 40 years
  to exclude multiple sclerosis and to assess if micro vascular compression
- CT - tumours of posterior fossa
- Haematological tests
- Biochemical tests
- Neurological – sensory testing and hearing
MRI scan

Diagnosis and differential diagnosis of trigeminal neuralgia

Zakrzewska JM.
Management of TN

- If patient under 40 years consider MS
- Patient presenting with sudden onset neuralgia
- You need to exclude
  - Space occupying lesions (always examine cranial nerve excluding 1 and 8)
  - Demyelination plaque (MS) using Gadolinium = T2 enhancement MRI
  - Vascular compromise of Vth ganglion
  - (Devor)
Carbamazepine - Tegretol

- First line treatment
- 70% of patients will respond with a reduction of pain
- Use doses from 300–800mg daily – four times daily
- Increase doses slowly
- Drug interactions common
- Failure often due to increased severity of pain
- Use retard formulation at night
Carbamazepine (CBZ)

- All patients will get side effects
- Drowsiness/tiredness
- Dizziness
- Zombie feeling
- Diplopia
- Ataxia
- Allergy 7%
RCTs in Trigeminal Neuralgia

**Drugs:**
- carbamazepine: effective
- lamotrigine: likely to be beneficial
- baclofen: likely to be beneficial
- pimozide: trade off benefit / harm
- tizanidine: unknown effectiveness
- proparacaine: unlikely to be beneficial
- tocainide: harmful

**Surgery:**
- Peripheral streptomycin: not beneficial
- Microvascular decompression: most effective
Ideal TN Surgery

- Widely available in many centres
- Minimally invasive – day stay or short admission
- Does not require a highly trained surgeon
- Immediate and complete relief of the attacks
- Allows all medications to be stopped
- Curative or low recurrence rate
- Causes no systemic complications e.g. hearing, stroke
- None or few local side effects
- Restores quality of life
- Requires no long term follow up
- Repeatable with no added risks
- Cost effective
Obliteration of the Gasserian Ganglion procedures

- Radiofrequency rhizotomy
- Glycerol rhizotomy
- Balloon compression
Obliteration of Gasserian ganglion OR MVD?
Probability of being pain free after surgery for trigeminal neuralgia.

- Cryotherapy 145
- Radiofrequency thermorhizotomy 2554
- Glycerol rhizotomy 385
- Balloon compression 50
- Microvascular decompression 2241
- Gamma knife surgery 292
Immediate operative complications

- Death – up to 0.5% in MVD
- Hypotensive changes, arrhythmias
- Hemorrhage – CVA
- Meningitis
- Headaches
- Deafness
- Herpes

Local trigeminal
- Sensory includes loss of corneal reflex
- Deaffrentation pain – pain in a numb area
- Motor

Outside trigeminal nerve
- 8th nerve
- 6th and 4th nerve – diplopia
- 7th nerve
Complications after surgery

- Local trigeminal
  - Sensory includes loss of corneal reflex
  - Deaffrentation pain – pain in a numb area
- Motor
- Outside trigeminal nerve
- 8th nerve
- 7th nerve
- 6th and 4th nerve – diplopia
If Patient is unable to have MVD...

- Gamma knife
- Sheffield ? 6 UK wide
### Classification of Chronic orofacial pain

<table>
<thead>
<tr>
<th>Neurovascular</th>
<th>Neuropathic</th>
<th>Idiopathic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tension HA</td>
<td>Trigeminal N</td>
<td>Burning Mouth S</td>
</tr>
<tr>
<td>Migraine</td>
<td>Typical / atypical PHN</td>
<td>TMJ pain</td>
</tr>
<tr>
<td>Cluster HA</td>
<td>Glosspharyngeal N</td>
<td>Persistent idiopathic (ATFP / ATO)</td>
</tr>
<tr>
<td>Giant cell arteritis</td>
<td>Post surgical N</td>
<td></td>
</tr>
<tr>
<td>SUNCT</td>
<td>Lingual inferior alveolar nerve injuries</td>
<td></td>
</tr>
</tbody>
</table>

**Trigeminal chronic pain**
The International Association for the Study of Pain (IASP) defines BMS as:

‘a distinctive nosological entity’ characterised by ‘unremitting oral burning or similar pain in the absence of detectable oral mucosal changes’ that can last at least 4-6 months.
Prevalence: BMS

- 1-15%  Tammiala-Salomen et al 1993
- 5.3%  - Locker & Grushka 1987,1988
- 0.7%  - Lipton et al 1993
- 2.6%  - Basker et al 1978
- 10.3% - Jaafar et al 1989
- 1.7%  - Richards & Scourfield 1996
Burning Mouth Syndrome

**Features**
- Spontaneous onset
- 4 month duration
- Normal appearance
- Supertasters/taste sensitivity

**Incidence**
- Women 15:1
- 1-5%
- Age >40-60yrs
- Post menopausal

**Altered Taste**
- Dry mouth
- Tongue thrusting
BMS causes

- Menopausal
- Supertasters
- Deficiency in Haematinics
- Psychometric - increased HADS scores
- Diabetes
- Neuropathy ??
Bar charts of the mean ± SEM of % area of NGF nerve fibres in control (n=9) and BMS (n=9) tongue. * P < 0.0001
BMS conclusions

- Corroborates small fibre neuropathy with loss of intra-epidermal lingual mucosal nerve fibres.
- Increased expression of TRPV1:NF reactive fibres and NGF within NF-IR fibres.
- Correlation reported pain and capsaicin allostynia with up regulation of TRPV1 and NGF.
- Need to establish functional links between the TRPV1, NGF and Nav 1.8 changes and BMS.
- Our findings indicate a path for increasing understanding and treatment of BMS.
Management of BMS

- **Systematic Review** and data in Clinical Evidence
- Cognitive behaviour therapy may be beneficial
- Reassurance
- Notriptyline first line but limited evidence for use of antidepressants
- ? Future neuropathic pain blocking agents
Chronic idiopathic facial pain (atypical facial pain AFP)

- **Character**
  - Intense - Nagging, dull, throbbing, sharp, aching

- **Severity**
  - Varies, mild to severe though patient can often sleep and function normally

- **Site, radiation**
  - no anatomical area

- **Duration, periodicity**
  - Constant >6 months
Management of AFP /AO

- Counselling and reassurance
  - CBT

- Medical
  - Antidepressants
    - Tricyclic antidepressants
      - Amitriptyline
      - Nortriptyline 10mg, 20mg, 30mg, 40mg each week. Maintain on 40mg nocte for 6 weeks before review

- Anticonvulsants
  - Oxcarbazipine
  - Carbamazepine
  - Gabapentin
  - Pregabalin

- Topical local analgesia

- Capsaicin
Chronic Idiopathic Facial Pain

- Provoking factors
  - Chewing, stress, opening mouth, tiredness
- Relieving factors
  - Rest, relaxation
- Associated factors
  - Pain in other areas, personality changes, life events, stress
Atypical Odontalgia (Dental Allodynia)

- persistent dental pain
- hypersensitivity to all stimuli
- may migrate from tooth to tooth
- no detectable pathology
  i.e. not a split tooth
Natural history of atypical odontalgia
Prognosis

- Chronic idiopathic facial pain – after one year 38% of patients pain free but 39% taking drugs to prevent relapse
- Feinmann and Harris 1984

12/15 required surgery to control their pain
TMD Natural History

- TMJ – less than 20% will continue to have continuous or increased pain
- One study showed that 3 years on only 5% still had TMJ pain
- Trigeminal neuralgia frequency of pain attacks increased with time
TMD

- Biopsychosocial
- Patient information
- BRA
- Cognitive behaviour therapy
- Antidepressants
  - Tricyclics – nortriptyline
  - SSRI – fluoxetine
TMJ Cochrane reviews


- NO EVIDENCE!
Non pharmacological methods

Psychological

Interpersonal strategies
  Communication
    reassurance
    sympathy
    understanding

Caring

Comfort

Consideration

Clinical Competence
Psychological factors in pain

- 20-50% of patients respond to Placebo!
- Increased anxiety / neuroticism / psychiatric morbidity
  - All predictive of persistent pain post operatively

- Cognitive behavioural therapy
- decreases pain in burns patients

- Increased use of OTC NSAIDs for headache with associated stress and poor physical fitness
Anxiolysis

- Non pharmacological
  - Interpersonal skills - reassurance
  - Hypnosis
  - Acupuncture
  - TENS

- Pharmacological anti-anxiety treatments
  - Single drug sedation (conscious)
  - Multiple drug sedation (deep)
  - Anaesthesia
Alternative analgesic therapies

- **Homeopathic**
  - Arnica reduces bruising and swelling

- **Hypnotherapy**
  - self hypnosis
  - induced hypnosis

- **Counselling**
  - Chronic pain patients may need counselling to improve their coping strategies

- **CBT**

- **Biofeedback**
  - training in changing function to reduce pain

- **Tens shown to reduce the discomfort of ID blocks**
Management – Alternative
Self empowerment Counselling

- Laughter
- Distraction
- Stress management – relaxation
- Exercise
- Social support
- Hypnosis
- Acupuncture
- Aromatherapy
- Pets
- Hobbies
The future

- Diagnose and Measure pain with fMRI
- Neural crest stem cells
  - Nerves
  - Immune cells
http://www.update-software.com/cochrane/

- Anticonvulsant drugs for acute and chronic pain Wiffen et al
- Interventions for the treatment of burning mouth syndrome Zakrzewska JM et al
- Management of TMD with splints, injections
Medical Management

Medical Management of facial pain
Evidence:
Cochrane library
http://www.update-software.com/cochrane/
Anticonvulsant drugs for acute and chronic pain Wiffen et al
Interventions for the treatment of burning mouth syndrome Zakrzewska JM et al

Clinical Evidence burning mouth syndrome and trigeminal neuralgia
Impact-based recognition of migraine
- How do headaches interfere with your life?
- How frequently do you experience headaches of any type?
- Has there been any change in your headache pattern over the last 6 months?
- How often and how effectively do you use medication to treat headaches

Acute treatment strategy
- Provide patient education and instruction
- Tailor intervention to the patient’s needs and select the best therapy for each patient
- Treat as early as possible in the attack
- Abort migraine symptoms and disability within 2–4 hours

Preventative treatment strategy
- Address patient expectations and compliance by providing patient education and instruction
- Develop a formal management plan
- Use headache diaries
- Reduce attack frequency, duration, severity and disability
- Prevent the development of CDH

Choice of acute treatments
- Mild headache: triptans, isomethyptene, NSAIDs, OTC combination analgesics
- Moderate to severe headaches: triptans or NSAIDS or OTC combination analgesics if previously successful

Choice of preventative medications
- Beta-adrenergic blocking agents
- Tricyclic antidepressants
DPF

- Aspirin dispersable 300mg (1g)
- Ibuprofen tabs 200mg
  - Propionic acid derivative
- Ibuprofen oral suspension 100mg/5ml
- Diflunisal tabs 250mg
  - Difluorophenyl derivative (Inc dry socket)
- Paracetamol tab 500mg
  - Acetaminophen – analine derivative
- Paracetamol sol tab 500mg
- Paracetamol oral susp 250mg/5ml
- Dyhydrocodeine tabs 30mg
- Pethidine tabs 50mg
  - Synthetic opioid
Management will depend on

- The future
- Prevention of chronic pain
- Earlier recognition
- Tailored individual treatment
Arterial spin labeling (cASL)

- cASL can quantify cerebral blood flow (CBF) changes in active brain areas responding to pain.
- Examine ongoing TME pain to provide an objective measure of pain.
Pre-surgical visits

ψ assessment nt & screening

cASL assessment nt

post-scan RNA

Surgical visits

ψ assessment nt & screening

pre-surgery RNA

wisdom tooth extraction & mucosa

cASL assessment nt

post-scan/surgery RNA
Measuring pain centre activity in the brain in man after third molar surgery

• Additional amygdala, hippocampus, brainstem, and V5 ROIs

ACC
S1
S2
PCC
THAL
Significant increases in post-surgical regional CBF in brain regions previously associated with pain (pain neuromatrix)

- Additional amygdala, hippocampus, brainstem, and V5 ROIs
Results

Significant increases in post surgical rCBF observed in:

- S1, S2, Thalamus, Insula, Anterior cingulate cortex
- Also in Amygdala and Hippocampus
- But NOT in control region
- Largest change seen in Thalamus
- No first or second order interaction of surgery for all ROIs

- Presurgery /post surgery
- Side (left or right)
- Hemisphere (left or right)
Genetics

- Post surgical pain (TMS)
- Burning mouth syndrome
- Post surgical painful neuropathy
- TN
- Cluster headaches, SUNCT and SUNA
Post surgical pain
Gene expression & VAS score relationships

- Correlation between 38 genes and VAS scores
- RED up regulated
- GREEN down regulated
- Left side correlation with VAS score for all 6 cASL maps
- Highest correlation reveals a gene BMX involved in regulation of IL6 in pts with RA